Purpose: Conventionally, symptoms occurring during the methacholine test are not taken into account when interpreting the test results. We examined whether the evaluation of methacholine-induced symptoms (MIS) added to the test interpretation based on the PC20FEV1 by assessing their prevalence, their similarity with symptoms justifying referral and their relationship with airway responsiveness.
causing a 20% fall in forced expiratory volume in one second (PC20FEV1) < 8 mg/mL or < 16 mg/mL, and a negative test as a non-response to the highest concentration. 2 In contrast with the definition of asthma, the interpretation of the MCT results relies solely on the percent drop in FEV1, without consideration of the symptoms justifying referral or those that may occur during the test. Although very popular, this approach ignores prior studies emphasizing the relevance of symptom evaluation during provocation tests. [3] [4] [5] [6] Furthermore, as it can only be assessed in subjects with AHR, a threshold index like the PC20FEV1 is of limited value to examine the relationship between symptoms and responsiveness at sub-threshold (ie < 20%) levels of fall in FEV1. This has practical importance because studies using non-censored measures of responsiveness such as the dose-response slope (DRS) found a significant association between asthma symptoms and airway responsiveness both above and below the threshold of AHR. 7, 8 In this study, we investigated whether the evaluation of methacholine-induced symptoms (MIS) in a population of adults with suspected asthma added to the interpretation of the test results based on the PC20FEV1. To do so we determined the prevalence of MIS in responders and nonresponders, checked their similarity with symptoms justifying referral, and examined their relationship with airway responsiveness assessed for all individuals, including those who did not reach the threshold of AHR.
| MAT ERI AL S A ND M ETH ODS

| Patients
The study was made up of 82 consecutive patients undergoing MCT at the Pulmonary Institute of the Shaare Zedek Medical Center, in Jerusalem. General practitioners, allergists and pulmonary specialists referred the subjects as part of the investigation of symptoms compatible with asthma. All subjects stopped short-acting bronchodilators for at least 8 hours, long-acting beta-agonists for at least 12 hours, and inhaled corticosteroids for at least 1 week before the MCT. No patient reported acute respiratory infections in the preceding 6 weeks. The hospital's Ethical Committee approved the study, but a consent form was not deemed necessary because the data to be collected were already included in the clinical MCT protocol.
| Methacholine challenge testing
The MCT was done using the two-minute tidal breathing protocol. 2 At baseline, at least three reproducible measures of forced vital capacity (FVC) and FEV1 were obtained. 9 Then the subject inhaled 0.9% saline followed by doubling concentrations of methacholine (0.03 mg/mL to 8 mg/mL) until a fall in baseline FEV1 by at least 20% occurred, or the last concentration of methacholine was inhaled. Aerosols (particle size 5 3.6 microns) were generated from a Hudson RCI micro mist nebulizer (Teleflex-Hudson RCI, Morrisville, NC, USA) with an output of 0.13 mL/min and were inhaled through the mouth through a mouthpiece for 2 minutes by means of tidal breathing. The PC20FEV1 was obtained from the log-dose response curve and AHR was defined as a PC20FEV1 < 8 mg/mL 2 . At end-test, responders and subjects reporting MIS inhaled four puffs of salbutamol (400 lg) from a metered dose inhaler. The methacholine concentration-response slope was computed by applying a mixed model through all data points obtained by plotting the percent fall in FEV1 from prechallenge FEV1 divided by the amount of methacholine inhaled.
| Questionnaire
Smoking history, respiratory health, the reason for the test, prechallenge symptoms and symptoms occurring during the test were evaluated using the ATS questionnaire for MCT 2 (Appendix). At baseline and immediately after the administration of each methacholine concentration, before spirometry, subjects were asked whether they were experiencing symptoms of either dyspnoea, chest tightness, cough or wheezing. In case of positive response, they were asked whether the symptoms were similar to those for which they consulted with a physician and that motivated the test. In addition, an experienced observer (AB) assessed wheeze sounds occurring during the MCT objectively by placing an electronic stethoscope (Littman Model 4000) over the patient's trachea, 2 cm above the suprasternal notch. 
| Clinical responsiveness
Based on MIS and airway responsiveness, subjects were classified into four groups of clinical responsiveness: (1) 'Asymptomatic non-responders' (ANRs): no symptom and/or wheeze by auscultation during MCT; PC20FEV1 8 mg/mL; (2) 'Asymptomatic responders' (ARs): no symptom and/or wheeze by auscultation during MCT; PC20FEV1 < 8 mg/mL; (3) 'Symptomatic non-responders' (SNRs): 1 symptom and/or wheeze by auscultation during MCT; PC20FEV1 8 mg/mL; and (4) 'Symptomatic responders' (SRs): 1 symptom and/or wheeze by auscultation during MCT; PC20FEV1 < 8 mg/mL.
| Statistical analysis
Statistical analysis was carried out using the Stata Package (Stata 13, College Station, Texas). Demographic characteristics were summarised using descriptive statistics, including means and standard deviations. To explore whether the pretest characteristics were predictive of the outcome of the MCT, we modelled separately being a reactor, experiencing symptoms during the test and the combination of the two outcomes with simple logistic regressions including each prechallenge characteristic at a time. In addition, three of the post hoc groups namely SRs, SNRs and ANRs were compared using Fisher's exact test or one-way analysis of variance (ANOVA) as relevant. To assess the relationship between MIS and airway responsiveness below the level of AHR (ie at < 20% fall in FEV1) we used a mixed model to compare the methacholine concentration-response curve slope (MCRS) of SNRs with that of ANRs over the whole range of the MCRS curve. The end-test FEV1 of SNRs and ARs was compared using t tests. Finally, multiple logistic regression analysis was used to determine the factors associated with the occurrence of asthma-like symptoms during the MCT. The discrimination power of the fitted logistic model was expressed by the area under the curve (AUC) of receiver operating characteristic (ROC) curves. A P value of less than .05 was considered significant.
| RES UL TS
Of the 82 patients studied, 26 (31.7%) were classified as ANRs; 6 (7.3%) as ARs; 16 (19.5%) as SNRs and 34 (41.5%) as SRs. Table 1 shows the baseline characteristics of the four groups. Being a female was significantly associated with both being a responder and being a symptomatic responder. A lower baseline FEV1 was significantly associated with symptoms during MCT and with being a SR, but not with being a responder. Finally, dyspnoea as a reason for the test was strongly and significantly associated with symptoms during the MCT, being a responder, and being a SR. No other associations were statistically significant. OR by decreasing baseline FEV1 in % predicted. * P < .05, ** P < .01. Table 2 shows the prechallenge characteristics of the four groups. Reporting previous, physician-diagnosed asthma and all respiratory symptoms in the two weeks preceding the test-except chest tightness-were related to symptoms during MCT and being a SR. These associations were less strong and not always significant with being a responder. Use of respiratory medicine was significantly related to the three outcomes, but this association was strongest for symptoms during MCT. Compared with ANRs, SRs presented significantly lower baseline FEV1 (P 5 .002), more dyspnoea as a reason for performing the MCT (0.039), more physician-diagnosed asthma in the past (P 5 .001) and more recent symptoms of dyspnoea (P < .001), wheeze (P 5 .03), or any symptom (P 5 .02), as well as more use of pulmonary medication (P < .001). In turn, SNRs looked very similar to SRs, no differences between the two groups emerging whatever the parameter considered (P values between .14 for pretest dyspnoea, and .98 for baseline FEV1). Conversely, SNRs differed from ANRs by showing significantly lower baseline FEV1 (P 5 .005), greater proportion of subjects reporting physician-diagnosed asthma (P < .001), and a greater proportion of subjects using respiratory medication (P 5 .03); for wheeze as a reason for the test the difference was of borderline significance (P 5 .06).
| Pretest characteristics
| Symptoms occurring during the MCT
Dyspnoea and wheeze detected by auscultation (Table 3) were, by far, the most common findings in each group, followed by cough, subjective wheeze and chest tightness. SRs and SNRs were similar in the proportion of subjects reporting symptoms during the test and in the proportion of subjects who recognized these symptoms as similar to those Figure 1 shows that the lower the dose of methacholine necessary to trigger symptoms the more likely the subjects were to be responders. Figure 2 shows that no linear relationship existed between the magnitude of percent fall in FEV1 and the onset of symptoms: some subjects presented symptoms at negligible falls in FEV1, while others remained asymptomatic until the FEV1 had fallen by values as great as 40%.
| Relationship between MIS and airway responsiveness below the threshold of AHR
This was evaluated by assessing the differences between the MCRS of the two groups of non-responders. As shown in Figure 3 , SNRs had significantly steeper MCRS (P < .001) values than ANRs a finding indicating relatively greater airway responsiveness in SNRs. Accordingly, SNRs had significantly greater mean percent fall in FEV1 at end-test (14.0 6 4.7) than ANRs (8.6 6 5.9) (P 5 .003).
| Predictors of 'asthma-like' symptoms during MCT
Multiple logistic regression analysis showed that three factors were significantly associated with the occurrence of MIS: (a) physician-diagnosed asthma in the past; (b) baseline FEV1% predicted; and (c) percent fall in FEV1 at end-test (Table 4 ). The discrimination ability of the logistic model, assessed by means of ROC curve, showed a curve close to the optimal left upper corner. The resulting AUC was 0.9494, indicating the excellent discrimination ability for the model (Figure 4 ).
| DI S CUS S I ON
In an outpatient population of adult patients referred for MCT because of suspected asthma, we found that 85% of the responders and 36% of the non-responders experienced MIS during the test, and that in 80% of the subjects in each group these symptoms corresponded to the symptoms FIGU RE 2 Scatter plot of percent fall in FEV1 versus inhaled methacholine (mg/mL) at first symptom in responders and non-responders reporting MIS. A wide variation in the fall in FEV1 is seen in both responders (0%-40%) and non-responders (0%-19%). In 10 responders and 8 non-responders, asthma-like symptoms manifested at decreases in FEV1 6% or lower FIGU RE 3 Mixed model assessing airway responsiveness below the threshold of AHR by computing the slope of the methacholine concentration-response curve in SNRs and ANRs. The curves show that the fall in FEV1 was significantly greater in the SNRs across the challenge. Since responsiveness is defined by the ratio of fall in FEV1 to the amount of methacholine inhaled, for a given methacholine concentration the greater fall in FEV1 in SNRs indicates a relatively increased responsiveness in these subjects compared with the ANRs FIGU RE 1 Proportion of responders according to the inhaled methacholine concentration at first symptom among subjects experiencing MIS. The numbers at each step correspond to the number of responders in whom symptoms first manifested either at that step or before. For instance, of the 10 subjects whose symptoms appeared at a methacholine concentration of 0.0625 mg/mL or earlier, 100% were responders. In turn, of the 23 subjects whose symptoms appeared at a concentration of 0.250 mg/mL or lower, 20 (87%) were responders justifying referral. Furthermore, among non-responders, SNRs were found to exhibit a steeper methacholine concentration-response slope than ANRs indicating a relative increase in airway responsiveness in the former group. These results suggest a possible role for symptom evaluation during the methacholine test. The observed high proportion of SRs is in keeping with studies showing high prevalence rates of histamine 3, 12, 13 or methacholine 4, 14, 15 induced symptoms in responders. It is also in agreement with studies showing that AHR is not only associated with paroxysms of bronchospasm and bronchial irritability 16 but also a major determinant of the clinical manifestations of asthma. 17, 18 Finally, our data confirm the common clinical observation that patients with AHR often complain of dyspnoea, cough, chest tightness and/or wheezing on exposure to stimuli such as irritants, cold air or exercise. Different factors may influence the perception of pharmacologically induced bronchoconstriction, including the speed and severity of the airway narrowing, dynamic hyperinflation, obesity, airway inflammation and emotional status, among others. 18 Our results build on previous studies by
showing that the onset of MIS may occur at very low levels of fall in FEV1, within the range of the within-day variation of the FEV1 in healthy subjects (Figure 2 ). This suggests that, in the initial steps of the bronchial challenge, the level of airway obstruction as assessed by the FEV1 did not fully explain the appearance of symptoms. This notwithstanding, the association between MIS and percent fall in FEV1 at endtest (Table 4) supports the view that the role of airway narrowing increased throughout the methacholine test. A small group of methacholine responders (n 5 6) denied MIS despite falls in FEV1 as large as 25%. One possible explanation is that these subjects underreported their symptoms. However, the short recall time resulting from the fact that the questionnaire was administered immediately after the inhalation of methacholine makes this possibility very unlikely and suggests these subjects were actually poor perceivers of acute airway narrowing. Poor perceptiveness of bronchoconstriction in hyperreactive subjects has been reported previously in subjects undergoing investigation for asthma 3, 15 or recruited from the general population. 13 Factors such as older age, airway inflammation and lower baseline inflammation could explain our findings. 19 However, while we did not measure airway inflammation, no differences existed between ARs and SRs in age and baseline FEV1 (Table 1) . Whatever the explanation, in practice, the important point is the identification of poor-perceivers themselves, as they may incur an increased risk of severe asthma attacks.
3,15
Explaining MIS in non-responders is not straightforward. Surprisingly, we found SNRs to be strikingly similar to SRs in many clinical parameters including the proportion of subjects (80%) in whom the MIS corresponded to the symptoms justifying referral; incidentally, this finding has been found to be associated with a positive test result. 4, 5, 14 In contrast, SNRs differed significantly from ANRs by having worse clinical parameters and milder AHR as detected by the methacholine concentration-response slope. The obvious question that arises from the above two comparisons is whether using the FEV1 as sole outcome measure in the methacholine test could have resulted in false negative tests in some SNRs. Indeed, other parameters such as, for instance, measures of airway resistance, have been reported to be more sensitive detectors of changes in airway calibre than the FEV1. [20] [21] [22] To quote but one study, Khalid et al 22 found that 27 of 138 subjects undergoing a methacholine test because of suspected asthma had a significant fall in sGaw FIGU RE 4 ROC curve expressing the discrimination power of the logistic model presented in Table 4 including, as dependent variable, the occurrence of asthma-like symptoms during the challenge and, as independent variables, physician-diagnosed asthma, baseline FEV1 in percentage of the predicted, and percent fall in FEV1 at the end of the challenge. The curve is displaced towards the left upper corner, giving an AUC of 0.9511, indicating the excellent discriminant power of the model (>52%) but did not drop their FEV1 by 20%. Second, for the methacholine test, a 12% drop in FEV1 has been found to be more accurate than the 20% threshold in separating healthy controls from subjects with exercise-induced bronchospasm. 23 Had we used the 12% value no fewer than 12 of our 16 SNRs would have turned into SRs. Finally, in the quality of global test, the FEV1 is not ideally suited to detect regional lung changes often associated with AHR. [24] [25] [26] Had they been present in our subjects, such changes could have explained both the clinical picture of SNRs and the poor correlation between wheezes-a sign produced locally in the central airways
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-and spirometry observed in SNRs and SRs (Table 2 ). However, as we did not measure regional lung function we can only speculate on this matter.
Our study provides a good illustration of the limited application of PC20FEV1 as an index of severity in patients with MIS who failed to achieve a 20% fall in FEV1 during the methacholine test. Using the MCRS, we were able to demonstrate that the SNRs had milder AHR compared with the ANRs. This finding is compatible with results from prior studies demonstrating a significant relationship between airway responsiveness-assessed by the DRSand asthma symptoms at sub-threshold levels of AHR in both children 7 and adults. 8 With the MCRS, we were able to assign a measure of severity of bronchial responsiveness to the subjects with falls in FEV1 of between 5% and 19% who otherwise would be merely classified as having normal responsiveness. Furthermore, in quality of continuous measure, the MCRS is better suited than a dichotomous index to monitor changes in airway responsiveness over time. This aspect has practical importance because we cannot rule out the possibility that the milder AHR in SNRs might be an early manifestation of airway inflammation carrying an increased risk of future asthma. Although only prospective, follow-up studies of SNRs can prove or disprove this hypothesis, there is evidence to suggest this might be the case. In one study, Khalid et al 27 found that 15 of 77 methacholine non-responders presenting asthma-like symptoms developed overt asthma over a 3-yr period; noticeably, 43% of patients with 10%-20% decline in FEV1 during the MCT eventually developed asthma. More recently, Peiman et al 28 reported a marked improvement in asthma symptoms and the disappearance of wheeze in methacholine nonresponders with clinically suspected asthma receiving treatment with high doses of inhaled fluticasone. However, as acknowledged by the respective authors, the above studies were somehow limited either by their retrospective design 27 or by the lack of a control group. 28 Furthermore, none of the studies assessed airway responsiveness in nonresponders experiencing symptoms during the test (ie SNRs), so the significance of milder AHR in this population remains unclear.
We think methodological errors did not influence our results. First, we used a well-established method for the provocation challenge protocol along with the standard ATS questionnaire. Second, although subject blinding to the incremental nature of the MCT was not feasible, all patients lacked blinding so this factor cannot explain the observed between-group differences. Finally, one may argue that because methacholine is a direct stimulus, our results are not generalizable. However, a previous investigation in mild asthmatics showed that symptom perception did not differ appreciably during the early response to a direct stimulus-histamine-and two indirect stimuli namely antigen exposure and exercise. 29 In conclusion, our study shows that symptom evaluation during the MCT helped identifying patients with milder AHR that would be overlooked by the PC20FEV1. Further prospective, longitudinal studies of SNRs should be conducted to determine the prognostic validity of this approach. To gather information on this matter, based on our results we planned a longitudinal, prospective study aiming to examine the effect of inhaled corticosteroids on SNRs outcomes [Bohadana A, Wild P, Izbicki G. Effect of inhaled corticosteroid on methacholine-induced symptoms, airway responsiveness and FE NO levels in methacholine non-responders: study protocol for a randomized controlled trial, (Submitted elsewhere)].
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